Affiliation:
1. Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali-844102, Bihar, India
2. Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India
Abstract
Abstract:
Type-2 diabetes mellitus is a prime factor for the development of Diabetic Nephropathy
(DN) that affects the vital organ namely the kidneys, and further alters the functions of the
nephron system. DN is nowadays becoming a challenge for scientists towards the world because
of its high pervasiveness and complexity of medication. Various risk factors are involved
in the initiation of pathogenic DN, which are associated with different pathways against drug
activity. Due to this DN becomes an unpredictable query to the researchers. SIRT1 is a silent
information regulator factor 2 related enzyme 1 (SIRT1) is nicotinamide adenine dinucleotide
(NAD+) dependent deacetylase that functions as an intracellular regulator of transcriptional activity.
An activated version of SIRT-1 improves the metabolic diseased conditions associated
with other molecular pathways. SIRT1 attenuates diabetic nephropathy in in vitro and in vivo
experimental models of diabetes containing Podocytes, Mesangial cells, and Renal proximal
tubular cells. SIRT1 shows nephroprotective effects in DN in part through deacetylation of
transcription factors i.e., imply in the disease like p53, PTP1B, FOXO, RelA, NF- kβ, STAT-3,
and PGC-1α/ PPARγ. It has been shown that some natural products like resveratrol and synthetic
compounds are activating the SIRT1, this further involved the cascade pathways to prevent
the DN. This review will help regarding the effectiveness of SIRT1as target in the prevention
and treatment of DN.
Publisher
Bentham Science Publishers Ltd.
Subject
General Health Professions
Reference187 articles.
1. Gheith O.; Farouk N.; Nampoory N.; Halim M.A.; Al-Otaibi T.; Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol 2015,5(1),49-56
2. Sadoul K.; Boyault C.; Pabion M.; Khochbin S.; Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 2008,90(2),306-312
3. Trevisan R.; Viberti G.; Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995,126(4),342-349
4. Zhu H.; Fang Z.; Chen J.; Yang Y.; Gan J.; Luo L.; Zhan X.; PARP-1 and SIRT-1 are interacted in diabetic nephropathy by activating AMPK/PGC-1α signaling pathway. Diabetes Metab Syndr Obes 2021,14,355-366
5. Akhtar S.; Siragy H.M.; Pro-renin receptor suppresses mitochondrial biogenesis and function via AMPK/SIRT-1/PGC-1α pathway in diabetic kidney. PLoS One 2019,14(12),e0225728
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献